Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

被引：49
|
作者：
Zhu, Andrew X. [1 ]
Finn, Richard S. [2 ]
Galle, Peter R. [3 ]
Llovet, Josep M. [4 ,5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[3] Univ Med Ctr, Mainz, Germany
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[6] Kindai Univ, Osaka, Japan
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(19)30165-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E191 / E191
页数：1
相关论文
共 50 条
  • [41] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
    Gerken, G.
    Zhu, A.
    Kang, Y-K
    Yen, C-J
    Finn, R.
    Galle, P.
    Llovet, J.
    Assenat, E.
    Brandi, G.
    Lim, H. Y.
    Pracht, M.
    Rau, K-M
    Merle, P.
    Motomura, K.
    Ohno, I
    Daniele, B.
    Shin, D. B.
    Abada, P. B.
    Hsu, Y.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 254
  • [42] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Finn, Richard S.
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Lim, Ho Yeong
    Pracht, Marc
    Rau, Kun-Ming
    Merle, Philippe
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Shin, Dongbok
    Gerken, Guido
    Abada, Paolo
    Hsu, Yanzhi
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma
    Plano Sanchez, Ana Isabel
    Velasco Roces, Lucia
    Zapico Garcia, Isabel
    Lazaro Lopez, Eva
    Calleja Hernandez, Miguel Angel
    Baena Parejo, Maria Isabel
    Pena-Diaz, Jaime
    ONCOLOGY LETTERS, 2018, 15 (06) : 8863 - 8870
  • [44] The Efficacy and Safety of Ramucirumab in Heavily Pretreated Advanced Hepatocellular Carcinoma
    Chen, Yen-Hao
    Tsai, Ching-Hua
    Chen, Yen-Yang
    Wang, Chih-Chi
    Wang, Jing-Houng
    Hung, Chao-Hung
    Kuo, Yuan-Hung
    ANTICANCER RESEARCH, 2023, 43 (07) : 3203 - 3212
  • [45] Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
    Llovet, Josep M.
    Yen, Chia-Jui
    Finn, Richard S.
    Kang, Yoon-Koo
    Kudo, Masatoshi
    Galle, Peter R.
    Assenat, Eric
    Pracht, Marc
    Lim, Ho Yeong
    Rau, Kun-Ming
    Borg, Christophe
    Hiriart, Jean-Baptiste
    Daniele, Bruno
    Berg, Thomas
    Chung, Hyun Cheol
    Godinot, Nathalie
    Wang, Chunxiao
    Hsu, Yanzhi
    Schelman, William R.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
    Gilabert, Marine
    Raoul, Jean-Luc
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 : 91 - 98
  • [47] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study
    Zhu, Andrew X.
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie Tung-Ping
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari David
    Pfiffer, Tulio Eduardo Flesch
    Okusaka, Takuji
    Kubackova, Katerina
    Trojan, Jorg
    Sastre, Javier
    Chau, Ian
    Chang, Shao-Chun
    Abada, Paolo
    Yang, Ling
    Hsu, Yanzhi
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma
    Liu, Chang
    Xiao, Guang-Qin
    Yan, Lu-Nan
    Li, Bo
    Jiang, Li
    Wen, Tian-Fu
    Wang, Wen-Tao
    Xu, Ming-Qing
    Yang, Jia-Yin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (11) : 1811 - 1819
  • [49] Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma
    Chang Liu
    Guang-Qin Xiao
    Lu-Nan Yan
    Bo Li
    Li Jiang
    Tian-Fu Wen
    Wen-Tao Wang
    Ming-Qing Xu
    Jia-Yin Yang
    World Journal of Gastroenterology, 2013, (11) : 1811 - 1819
  • [50] A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
    Andrew, Zhu
    Peter, Galle
    Masatoshi, Kudo
    Richard, Finn
    Ling, Yang
    Paolo, Abada
    Josep, Llovet
    ANNALS OF ONCOLOGY, 2016, 27 : 83 - 83
12345